OUR REG A+ CAMPAIGN WILL CLOSE IN 32 DAYS

Fisher Wallace has hit multiple strategic milestones over the past year (including the completion of 3 clinical trials and the launch of Version 2 product development) and has raised over $3.3M.

"5 Health-Tech Startups to Watch in 2021"

- Entrepreneur Magazine

"One of four technologies innovating mental health."

- Forbes

"But since I couldn't stop talking about my good mood and hypercharged focus, my friends stopped laughing and started asking if they could borrow it. I'm reluctant to let go of my stimulator, however."

- ELLE Magazine

Investors who invest $1500+ may choose to receive a free Version 1 or Version 2 device as a perk.

Disclaimer: These testimonials may not be representative of the experience of other customers and is no guarantee of future performance or success. In addition, this investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.

35 DAYS REMAIN UNTIL WE CLOSE OUR CAMPAIGN

Dear Investors, I invite you to read a few of the hundreds of verified reviews from our patients on fisherwallacereviews.com.  Here's one:

"This device works. I've been on various meds over the years and the device has improved my well being significantly over the best drug results I've had, and without the biochemical disruption caused by drugs that means side effects. Even with only half the recommended frequency of use, it has returned my mental energy and desire to actively pursue my goals and hobbies."
- Jeff Sterner (Real Patient)

We are closing our campaign in 35 days - as always, if you invest $1500+ you may choose to receive our Version 1 or Version 2 device for free.

Thanks for your consideration.

Best, 

Kelly Roman

Cofounder & CEO, Fisher Wallace Laboratories

Disclaimer:  

This testimonial may not be representative of the experience of other customers and is no guarantee of future performance or success. 

In addition, this investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.

39 Days Remain Until We Close Our Campaign

(Version 2 concept above)

Dear Investors,

Apple and the other large tech behemoths have so far avoided diving into medical devices because of the complexities and risks of running clinical trials and navigating the FDA regulatory process - it's outside of their current wheelhouse. But their shareholders' demands for growth remain relentless - sooner or later, these companies will likely focus much more on this space.  They have already more than dipped their toe into healthcare - whether Apple's HealthKit, Google's acquisition of Fitbit or Amazon's acquisition of PillPack.

Our Version 2 device is going to look like something Apple might build in terms of design quality, build and user experience - but with our own unique brand DNA. That's why we are working with Eric Fields, the industrial designer behind Beats and Nest products, and Pearlfisher, one of world's leading branding firms - to take our hardware to a level not seen before in prescription medical devices. 

Compared to Apple, we are a microscopic company - but we are still doing something, with your support, they should be doing, with a level of design and clinical and scientific validation that is truly world-class.

We are closing our campaign in a few weeks. If you invest $1500+ you will be eligible to receive Version 2 (or Version 1) for free.

Thanks for your consideration,

Kelly Roman

Cofounder & CEO, Fisher Wallace Laboratories

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.

We just surpassed $3.2M raised in our current Reg A+, bringing our total to over $4.2M raised between our previous Reg CF and our current campaign.

Successfully raising this amount is a profound competitive advantage - none of our direct competitors have raised significant capital, and as a result, we are leap frogging them with our clinical research and Version 2 product development.

<46 DAY REMAIN UNTIL WE CLOSE OUR CAMPAIGN

Our technology is FDA-Cleared to treat anxiety, depression and insomnia - invest $1500+ and receive a free Version 1 once your investment is disbursed or Version 2 when it's released next year.

Best regards,

Kelly Roman

Cofounder & CEO, Fisher Wallace Laboratories

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.

<49 Days Remain

We are closing our equity crowdfunding campaign on October 26, 2021. If you invest $1500+ you will receive our Version 2 (or Version 1) device for free.

Reasons to invest:
 

- Experienced leadership team

- 3 Clinical trials completed during the pandemic

- Version 2 from the designer of Beats and Nest products (Eric Fields)

- Version 2 branding by Pearlfisher

- Free prescription process integrated with checkout

- Mental health treatment is the #1 healthcare expense in the US (more than cancer, diabetes or heart disease)

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.

Mental Health is the #1 healthcare expense in the US and rates of anxiety, depression and insomnia have surged during the pandemic. Fisher Wallace is helping to lead a revolution in improving patient care at home.

"5 Health-Tech Startups to Watch in 2021"

- Entrepreneur Magazine

"Columbia University Associate Clinical Professor of Psychiatry Richard P. Brown says he has used the device with 400 severely depressed patients and that more than 70% find relief -- about twice the rate of anti-depressants."

– The Wall Street Journal

"But since I couldn't stop talking about my good mood and hypercharged focus, my friends stopped laughing and started asking if they could borrow it. I'm reluctant to let go of my stimulator, however."

- ELLE Magazine

"One of four technologies innovating mental health."

- Forbes

Disclaimer: This testimonial may not be representative of the experience of other customers and is no guarantee of future performance or success.

In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion

Dear Investors,

We launched our new prescription process last week which allows customers to be screened and receive a prescription if they qualify for free (to them) directly during the checkout process.  We had two minor kinks we ironed out over the past few days, such as the need to pass along the full state name instead of the state's abbreviation to our telemedicine partner, but otherwise there have been no major technical hiccups. 

Sales are healthy and appear to validate the transition to a fully integrated prescription process - but it will take a month or so to get a clear picture of the true impact on our e-commerce conversion rate. Thanks to our telemedicine partner, B2BMD, we now have a truly modern e-commerce experience for a prescription product - which as far as I know is unique among medical device companies. 

There are a lot of wellness devices and apps out there - but very few FDA-regulated, prescription products for mental health outside of generic drugs which have many disadvantages.  I've always believed that our opportunity was not to succumb to the temptation of building a slick wellness brand with flimsy scientific claims, but to focus on the prescription product space that can actually make strong medical claims, and investing in the required clinical trials before we even started to redesign how our product looked. Now that we have the clinical trial data  - thanks to our StartEngine investors - and our new prescription process in place, we are moving full steam ahead on Version 2 and I can't wait to share more images as they become available.  Science first!  Good looks second!

Our campaign is closing in <55 days.  As always, if you invest $1500 or more, you are eligible to receive a free Version 2 device.

Best, Kelly

CEO Fisher Wallace

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.  

Dear Investor,

Having successfully raised over $3 million while hitting a number of other key milestones over the past year, I've decided it's the right time to wind down our current equity crowdfunding campaign - we will keep the campaign active for 60 more days, and close it on 10/26/21.

Fisher Wallace will have the option of launching a new campaign at a later date at a higher valuation, and we may also choose to list Fisher Wallace on StartEngine's Secondary marketplace where shares may be traded.

As you can see from the image above, Version 2 product development is well underway; we have successfully completed three clinical trials over the past year, with a particularly strong result in our anxiety trial; we've launched a new study with a major metropolitan police department; we've integrated a free prescription process directly into our checkout; we've hired great new talent on the marketing and operations side of our business.

This Fall, we will move into the engineering phase of product development, start developing the mobile app and our new website, and complete the Version 2 branding process (with a new brand name which we've trademarked and I'll announce in a formal press release early next year).

I will continue to keep you updated on our progress. As always, if you decide to invest $1500+ in Fisher Wallace, you are eligible to receive our Version 2 device for free. We have raised capital successfully in large part because our loyal customers decided to support our growth and the future of our technology - and for that I feel tremendous gratitude.

Sincerely,

Kelly Roman
CEO, Fisher Wallace

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.  

While the company has signed a quotation agreement to trade the securities offered on StartEngine Secondary’s new alternative trading system (the “ATS”), a company which intends to be quoted on the marketplace will be subject to certain requirements which the company may or may not be able to satisfy in a timely manner. Even if a company is qualified to quote its securities on the market, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.

Dear Investors, 

After months of preparation, our telemedicine partnership is now live on fisherwallace.com - our customers may now obtain a prescription during checkout at no additional cost. 

Fully integrating a state-by-state, asynchronous and synchronous telemedicine process directly into our checkout is a major milestone for Fisher Wallace - it brings increased efficiency to the purchase process and is highly scaleable. We no longer need to ask patients to leave our website to obtain a prescription (at additional cost to them). The cost of the prescription is now bundled into the cost of the device. This allows us to scale our marketing efforts with much greater confidence - to improve Version 1 sales now and set the stage for a successful Version 2 launch next year.

Best regards,

Kelly Roman

CEO, Fisher Wallace Laboratories

"But since I couldn't stop talking about my good mood and hypercharged focus, my friends stopped laughing and started asking if they could borrow it. I'm reluctant to let go of my stimulator, however."

- Nina Burleigh, ELLE Magazine

Read the article here.

As always, when you invest $1500+ in Fisher Wallace, you will receive a free device.

Disclaimer: This testimonial may not be representative of the experience of other customers and is no guarantee of future performance or success. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. 

Dear Investors,

As you can see, the first t-shirt arrived. As mentioned previously, we are in the process of submitting data to scientific journals so additional details will be forthcoming upon publication - but we're still having some early fun here celebrating our clinical trial results over at the Laboratory.

Here are a few key updates:

- The telemedicine service that will become a seamless part of the checkout process on fisherwallace.com is undergoing final API integration today and should be live next week. This allows for our customers to obtain a prescription from a third party provider licensed in their state without having to leave the checkout process (similar to Hims&Hers). That should increase our e-commerce conversion rate and provide a much better customer experience.

- We have submitted our new Version 2.0 brand name (still confidential), generated in collaboration with branding firm Pearlfisher, to the US Patent and Trademark Office (as well as in various European markets). It's a single syllable word that truly captures the essence of the brand and mission of the company. Pearlfisher is now diving into creating the logo, iconography, tag line, overall messaging for our marketing materials, and other branding assets.

- Industrial design on Version 2 is nearing completion of Phase 1, which means we are close to a final form factor concept which is wireless, features an integrated cell phone speaker (to provide audio cues to the user such as when the treatment session is complete, or if there are any conductivity issues requiring re-wetting the electrode sponges, etc), LED lighting, Bluetooth and, perhaps best of all, the ability to be offered in several color choices. In short, this will be a device people will be delighted to put on and even wear in public, and should greatly reduce any fear generated by seeing a red and black wire.

- Mechanical and electrical engineering workflows are now beginning, based on this evolved design concept - engineering will actually cost significantly more than industrial design, but we are working with a firm that has engineered many well known wearables to ensure world-class performance, fit and finish.

Thanks for your consideration, and as always, if you invest $1500 or more in our campaign, you are entitled to receive either a free Version 1 device (shipped within 4 weeks of your investment) or reserve a free Version 2 device.  At this point our Version 2 ship date looks like it will be April at the earliest, and more likely May 2022.  I'll keep you apprised of this as development continues.

Best regards

Kelly Roman

CEO, Fisher Wallace

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. 

Given the stunning trend for Generalized Anxiety Disorder (GAD) prevalence pre-Covid v. post-Covid, we are expecting another surge in GAD as a result of the Delta (and possible Lambda) variant.

Delta variant cases are skyrocketing in many US geographies. Published research on GAD prevalence pre v. post COVID show an enormous uptick prior to Delta:  

Generalized Anxiety Disorder (GAD) affected 3.1% of US adults prior to the COVID-19 pandemic, with only 43.2% of these patients actually receiving treatment (https://adaa.org/understanding-anxiety/facts-statistics). In April 2020, the rate of GAD among US adults is reported to have risen to 17.9% (https://pubmed.ncbi.nlm.nih.gov/33480832/).

Our most successful clinical trial conducted during the pandemic studied GAD. We do not welcome the mental health impacts of rising Delta variant COVID cases - however our tech is on the front line of treating patients in the midst of this new stressor. We welcome our ability to treat patients.

PS: A video update on real time business results will be posted before end of week by our CEO, Kelly Roman.

Onwards and upwards.

Dear Investors,

Our technology is utilized by patients across generations. Our last campaign update featured an Iraq and Afghanistan veteran, Logan Shield - we now invite you to listen to Mike Davis, a Vietnam veteran, as he briefly shares his experience of using our device.:

Our CEO Kelly Roman will post another video update next week with exciting real time news about the business.

Have a great weekend!

Disclaimer: This testimonial may not be representative of the experience of other customers and is no guarantee of future performance or success. 

Dear Investor

We invite you to watch the short video of retired US Army General and board-certified psychiatrist Dr. Stephen Xenakis discuss our technology's advantages for veterans suffering from depression, anxiety and/or insomnia.

Dr. Xenakis served 28 years in the United States Army as a medical corps officer. He held a wide variety of assignments as a clinical psychiatrist, staff officer, and senior commander including Commanding General of the Southeast Army Regional Medical Command. 

As always, if you invest $1500+ you will receive a free Fisher Wallace device.

Thanks for your consideration,

Kelly Roman

Cofounder & CEO, Fisher Wallace Laboratories

Disclaimer: This testimonial may not be representative of the experience of other customers and is no guarantee of future performance or success. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. 

Dear Investor,

We invite you to view a short clip of our technology's appearance on the THE DOCTORS (CBS):

Thanks for your consideration!

As always, you will receive a free device with a $1500+ investment on StartEngine.

Disclaimer: This testimonial may not be representative of the experience of other customers and is no guarantee of future performance or success. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Dear Investor,

A Fisher Wallace patient was recently interviewed for a European documentary (our technology has received approval for sale over-the-counter in Europe) - we invite you to listen:

As always, investors who invest $1500 or more in our StartEngine campaign are shipped a free Fisher Wallace device (retail price is $499).

Thanks for your consideration!

Disclaimer: This testimonial may not be representative of the experience of other customers and is no guarantee of future performance or success. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Dear Investor,

We invite you to listen to Logan Shield, a US Marine who used our technology to overcome depression, anxiety and insomnia (5 minute video):

Our medical advisory board includes a retired US Army General and we look forward to serving many more Veterans as we scale our business. 

Best regards,

Kelly Roman

Cofounder & CEO

Fisher Wallace Laboratories, Inc.

This testimonial may not be representative of the experience of other customers and is no guarantee of future performance or success.

In his latest update, Fisher Wallace CEO Kelly Roman discusses:
 

• It's official: we have a new telemedicine partner integrating a seamless prescription process into our checkout (on fisherwallace.com). Think "Hims&Hers of medical devices" - starting with our own device.

• Our police department study, now approved by the IRB, is recruiting 3 additional major metropolitan police departments to join the study. So at the minimum we have one department involved, and at the maximum, four departments. 

• One of the studies we performed during the pandemic has recorded a p-value of less than 0.05. This is MASSIVE news (but many details need to remain confidential until the study is published). More on what that means in the video. T-shirts are involved.

As always, investors who invest $1500 or more in Fisher Wallace's Reg A+ campaign qualify to receive a free device and may choose either Version 1 (ready to ship now)  or Version 2 (anticipated ship date is April 2022). 

Please leave a comment on our StartEngine page if you have any questions!

Disclaimer: This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Why do over 70,000 patients use our FDA-Cleared wearable device to treat symptoms of depression, anxiety and/or insomnia? 

To be easier to get along with.

To enjoy the time they spend with their children.

As a way to relieve anxiety without relying on alcohol or other forms of "self-medication."

To stop having a hair-trigger temper.

...And for many, many other good reasons.

Our technology works by stimulating the brain to produce key neurotransmitters (such as serotonin) while lowering cortisol (the stress hormone) without causing any serious side effects.

Our brains are electrical - that's why we developed an FDA regulated, electrical stimulation medical device to treat  mental health symptoms that's safe, effective, affordable and easy-to-use.

As always, when you invest $1500 or more in Fisher Wallace, we will ship you a free Version 1 device (available now) or our upcoming Version 2 device (anticipated ship date of April 2022). 

>>> Version 2 is being designed by Eric Fields, the award winning industrial designer of Beats and Nest products.

Please stay tuned for the next video update from our CEO, Kelly Roman - and if you missed his last one, we encourage you to watch his previous update right below this one on our StartEngine campaign page.

Have a great week!

BTW, Fisher Wallace was recently named one of "5 Health-Tech Startups to Watch in 2021" by Entrepreneur Magazine.  Read the article here.

Disclaimer: This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

In his latest update, Fisher Wallace CEO Kelly Roman discusses:
 

• 2021 financial performance and a new approach to managing marketing talent

• How seamless telemedicine integration may impact device sales in Q3

• First Version 2 concept art and thoughts on new electrode material

• Building an app that requires minimal usage while providing rich data, because high cell phone usage is antithetical to mental health

• New 200-subject police study finally gets IRB approval

As always, investors who invest $1500 or more in Fisher Wallace's Reg A+ campaign qualify to receive a free device and may choose either Version 1 (ready to ship now)  or Version 2 (anticipated ship date is April 2022). 

Please leave a comment on our StartEngine page if you have any questions!

Equity research analyst Stavros Georgiadis recently contributed an article to InvestorPlace that identifies Fisher Wallace as one of

The 7 Best Startups You Can Buy On StartEngine Right Now

Several of the companies on the list just closed their campaigns on StartEngine, so the list is significantly shorter now.

Fisher Wallace is currently developing a Version 2 medical device to treat mental health conditions, to replace Version 1 which is available now on fisherwallace.com (where it's sold over 70,000 units to date). Version 2 is being designed by Eric Fields, the designer of Beats and Nest products, and will feature a new brand name and an app to track performance.

Please stay tuned for the next video update from Fisher Wallace CEO Kelly Roman, arriving soon!

Disclaimer: This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

In this latest update, Fisher Wallace CEO Kelly Roman discusses:

- The value that advisor Peter Rojas brings to the enterprise

- Seamlessly integrating both "asynchronous" and "synchronous" prescription processes into the website and app experience

- The Version 2 brand name 

- Industrial design's focus on building a wireless Version 2 device

- Concept for app that includes symptom tracking, cognitive performance testing and curated digital health products and services 

Happy Father's Day!

Dear Investors,

Here are the results of a 4-question survey we sent this week to our customers who have not returned their device for a refund and have opened one of our newsletters within the last 30 days. There was no reward / material incentive for completing the survey. 621 customers completed this survey.

Survey Highlights:

41.9% of our customers consider our device as important as their cell phone

76.5% of our customers intend to use our device for the rest of their lives

38.5% of our customers experience cognitive benefits from using our device over-and-above mental health symptom reduction

27.2% of our customers consider our device more important than their cell phone

This confirms something incredibly important: the majority of our customers are customers for life.

Thanks for your consideration.

Best, 

Kelly Roman

Cofounder and CEO, Fisher Wallace

Dear Investor,

I'm pleased to announce that Peter Rojas has formally joined Fisher Wallace as an advisor. Peter is a partner at Betaworks Ventures, a venture capital fund investing in the future of how we live, work, and play online; among other investments, Betaworks Ventures was a seed investor in Giphy (acquired by Facebook in 2020).

Prior to Betaworks Ventures, Peter was VP of Strategy at AOL and Co-director of Alpha, the company's experimental products group. He is also the co-founder of several successful startups, including Weblogs Inc. (acquired by AOL in 2005), where he created and was editor-in-chief of both Engadget and Joystiq; Gizmodo/Gawker Media (now part of G/O Media); music discovery service RCRD LBL; and gdgt, a social commerce platform (acquired by AOL in 2013).

I've known Peter for many years, and he's coming on board Fisher Wallace at a critical moment for our company - and our country - as we work to elevate the understanding and treatment of mental health.

Peter and I recorded our Zoom conversation yesterday as a means of introducing him to our tens of thousands of customers, our thousands of individual investors on StartEngine, and other stakeholders - you may watch the 25 minute exchange on Vimeo (I'll also post it as a podcast and update on StartEngine itself shortly). Warning: it was my first time recording a zoom and the camera does not switch back to who's actually speaking as regularly as it should ;)

Peter believes Fisher Wallace has the potential to become the "Peloton of mental health" - we are working to realize this potential via a combination of new FDA-Approval and re-Clearance applications, rebranding from Pearlfisher (Blue Bottle Coffee, Seedlip), Version 2.0 industrial design from Eric Fields (Beats, Nest), and new app and website development for our upcoming prescription and wellness brands.

Here are a few highlights from my Zoom with Peter:

- Peter is excited by the "end-to-end solution" approach to mental health and wellness that Fisher Wallace is currently developing, and believes "the moment is here" culturally in the US.

- Fisher Wallace is not simply a device, "it's a practice."

- In a recent survey of hundreds of Fisher Wallace customers, more than 75% of respondents declared that they intend to use their Fisher Wallace device for the rest of their lives.


As always, if you invest $1500 or more in Fisher Wallace on StartEngine, you will receive a free device (you may opt for Version 1 or Version 2, with anticipated release of Version 2 by end of Q1 2022).

Sincerely,

Kelly Roman

Cofounder and CEO, Fisher Wallace

Dear Investors,

We invite you to listen to the interview with our CEO Kelly Roman on the AWAKEN YOUR ALPHA podcast! Kelly opens up about his own challenges with depression when he was in his twenties and how it inspired him to build the company. Enjoy!

Dear Investors,

Following is a general business update from Kelly Roman, Co-Founder and CEO of Fisher Wallace - the first in what will be become a weekly video update on StartEngine. Thanks for your consideration and please leave any questions in the comments section of our campaign page!

Dear Investors,

We invite you to read a new article on Entrepreneur.com about Fisher Wallace. This is an article we sponsored as a means of educating the Entrepreneur readership about our campaign - thanks for your consideration!

3 Reasons Why Executives are Using a Medical Device to Manage Mental Health

Fisher Wallace has engaged renowned industrial designer Eric Fields to design our Version 2.0 device.

Eric Fields is one of the preeminent industrial designers of the past decade - recognition for his work includes back-to-back Red Dot Awards (the highest honor for an industrial designer) for the Nest Thermostat and the Beats Pill.

We look forward to Eric bringing Version 2.0 to life in physical form, in concert with the rebranding currently underway by Pearlfisher.

By integrating world-class design, branding, clinical research conducted during the pandemic, and new FDA Approval and/or Clearance, we believe our Version 2.0 device will set a new standard of care for mental health treatment.

Best,

Kelly Roman

CEO

"5 Health-Tech Startups to Watch in 2021"

- Entrepreneur magazine

Dear Investor,

Entrepreneur magazine just named Fisher Wallace one of "5 Health-Tech Startups to Watch in 2021."

Thanks for your continued interest in our mission of becoming a new standard of care for depression, anxiety and insomnia.

Best regards,

Kelly Roman
CEO, Fisher Wallace Laboratories

Dear Investor,

I am pleased to report that the FDA has officially filed our depression approval application, which means the Agency has found it to be complete - the first major hurdle of the submission process. FDA reviewers will now proceed with a substantive review of the application.

"A filing review was conducted on your submission...and it was found to contain all of the information needed to proceed with the substantive review." 

Fisher Wallace has succeeded in raising over $2.2 million via our SEC-regulated equity crowdfunding campaign which sells shares in Fisher Wallace to the public. These funds allowed us to execute our three clinical trials which were submitted to FDA on March 19th, 2021, and we are now focused on Version 2 product development. I will have an additional announcement regarding product developing in the coming week.

Investors who purchase $1500 of Fisher Wallace equity are eligible to receive a free device - and may opt to receive a free Version 2 device.

Best regards,

Kelly Roman
CEO, Fisher Wallace Laboratories

We invite you to listen to Andrea Samadi's review of her month-long trial with the Fisher Wallace device on her podcast, Neuroscience Meets Social and Emotional Learning. Andrea used a Fitbit to measure her sleep at baseline for 3 days before measuring the effect of the Fisher Wallace device on her sleep over the following four weeks.

We invite you to listen to The Bright Side of Life podcast interview with Fisher Wallace CEO Kelly Roman as he discusses the benefits of using the device.

Dear Investor,

I am pleased to announce that Fisher Wallace has signed an agreement with StartEngine to participate in StartEngine Secondary, a new investor trading platform that can match orders for buyers and sellers of Fisher Wallace securities. We will not join this platform until we close our current equity crowdfunding campaign. Listing on StartEngine Secondary may provide shareholders access to a marketplace for their shares.

I am also pleased to report that we completed our March 19th FDA submissions for all three of our indications - depression, anxiety and insomnia - in partnership with our regulatory team at Hyman, Phelps and McNamara (recently named the #1 FDA law firm by USNews and World Report).

We produced positive data from all three of our clinical trials, and I feel particularly proud of the results of our Generalized Anxiety Disorder study, in which more than 70% of subjects experienced a 50% or greater reduction in symptoms by the end of week 8. While I cannot provide any assurance that our bid for FDA Approval will succeed, I believe we are in a strong position.

There was no worse or more challenging time, operationally or societally, to conduct these trials. There was also no better time to scientifically validate a low risk, affordable, highly accessible, easy-to-use treatment for depression, anxiety and insomnia that could be prescribed via telemedicine and shipped directly to a patient’s door. The events of the past year underscored the need for an alternative to existing treatment and modalities which have failed to help many patients, and the study results demonstrated that the Fisher Wallace device could help alleviate mental health conditions.

As always, should you decide to invest $1500 or more in Fisher Wallace, you will receive a free device - you may choose to receive Circadia® or opt to receive a Version 2.0 device when it becomes available.

Thanks for your consideration,

Kelly Roman

CEO, Fisher Wallace

Disclaimer re: StartEngine Secondary: While the company has signed a quotation agreement to trade the securities offered on StartEngine Secondary’s new alternative trading system (the “ATS”), a company which intends to be quoted on the marketplace will be subject to certain requirements which the company may or may not be able to satisfy in a timely manner. Even if a company is qualified to quote its securities on the market, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.

Dear Investors,

We know that the impact of the pandemic - not just the virus itself but the resulting isolation and economic impacts - have taken a serious toll on the nation's metal health - especially among young people. Here's an excerpt from a recent report from The Henry J. Kaiser Family Foundation:

"Young adults have experienced a number of pandemic-related consequences, such as closures of universities and loss of income, that may contribute to poor mental health. During the pandemic, a larger than average share of young adults (ages 18-24) report symptoms of anxiety and/or depressive disorder (56%). Compared to all adults, young adults are more likely to report substance use (25% vs. 13%) and suicidal thoughts (26% vs. 11%). Prior to the pandemic, young adults were already at high risk of poor mental health and substance use disorder, though many did not receive treatment."

A few years ago, we launched a brief collaboration with the streetwear brand Mishka to address the mental health needs and cultural taste of younger consumers. This limited edition of 100 devices sold out very quickly and generated coverage in Hypebeast, but we refrained from expanding this product line until we could generate the clinical data needed to fully support the treatment.

We now have the clinical data. As Fisher Wallace pivots from completing its clinical trial submissions to focusing on Version 2 product development, we will be focused on making our solution appealing - from a hardware and app perspective - to a younger generation. Our product development process will be informed by the learnings gained from our partnership with Mishka and the heightened need for our solution in the current and post-Covid world.

Thanks for your consideration,

Kelly Roman

CEO, Fisher Wallace 

Dear Investors,

I am pleased to announce that the results of our anxiety study are strong enough for Fisher Wallace to submit them to FDA by March 19th - we believe the results will support approval for the treatment of Generalized Anxiety Disorder.

However, there can be no assurances that FDA will in fact approve our application for the proposed clinical use or accept the application for filing, or, if FDA does file the application, that the Agency will not identify deficiencies in the application that will compel us to generate additional clinical analyses or data, or provide other information to address deficiencies FDA may identify.  

I will update you again when I have information regarding our Insomnia clinical trial - our biostatistics team, NAMSA, is still processing the Fitbit data from this trial.

Thanks for your consideration,

Kelly Roman
CEO, Fisher Wallace

Dear Investors,

While I am unable to divulge detailed information regarding the results of our Major Depressive Disorder (MDD) clinical trial prior to publication by a peer-reviewed journal, I am pleased to announce that the results of the study are strong enough for Fisher Wallace to submit to FDA by March 19th and that we believe the results will support approval for the treatment of Major Depressive Disorder. However, there can be no assurances that FDA will in fact approve our application for the proposed clinical use or accept the application for filing, or, if FDA does file the application, that the Agency will not identify deficiencies in the application that will compel us to generate additional clinical analyses or data, or provide other information to address deficiencies FDA may identify.  

I will update you again when I have information regarding our Generalized Anxiety Disorder trial - our biostatistics team, NAMSA, is preparing this information now.

Thanks for your consideration,

Kelly Roman
CEO, Fisher Wallace

This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please see the Fisher Wallace, Inc  offering circular as well as the risks associated with this offering. 

Dear Investors,

Here's a clip we obtained from the producers of the amazing new documentary entitled SLEEP AT ANY COST that will be released in the US in the coming months. This remarkable segment profiles Fisher Wallace and one of our patients who successfully treated her mood and sleep symptoms. Enjoy!

Thanks for your consideration,

Kelly Roman

CEO, Fisher Wallace

This Reg A+ offering is made available through StartEngine Primary, LLC. It is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. Please review the offering circular before investing.

Hi, I hope you are well. 

I'm pleased to announce that we have successfully recruited enough patients to fill our three clinical trials. A number of patients are still in the process of migrating from becoming eligible (through automated questionnaires) into telemedicine interviews and subsequent approval for enrollment, but we have enough patients in process to meet our enrollment goals.

As I've mentioned before, in a recent survey of 5,470 respondents performed by the CDC between April-June 2020, 30.9% of respondents reported symptoms of anxiety or depressive disorder - a 3X increase since the pandemic began. The nation is in the midst of a mental health emergency resulting from COVID-19 and Fisher Wallace is working tirelessly to scientifically validate a safe, effective, low cost solution that may be delivered directly to patients' homes. 

Thanks for your consideration!

Best regards,

Kelly Roman

CEO, Fisher Wallace

In a recent survey of 5,470 respondents performed by the Centers for Disease Control and Prevention (the "CDC") between April-June 2020, 30.9% of respondents reported symptoms of anxiety or depressive disorder - a more than 3X increase versus before the pandemic.

You may view the data here: https://www.cdc.gov/mmwr/volumes/69/wr/mm6932a1.htm

This report sheds light on the massive need Fisher Wallace is working to address - and why our current clinical trials for depression and anxiety are so critical to our mission.

Best regards,

Kelly Roman

CEO, Fisher Wallace Laboratories

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Dear Investors,

When you invest $1500 or more in our Reg A+ campaign, you will receive a free Fisher Wallace device (our wellness brand Circadia® which is technologically identical to the Fisher Wallace Stimulator but does not require a prescription, as it is intended for stress and sleep management). We are allowed to ship your device once your investment has be disbursed to Fisher Wallace by StartEngine - this is when the investment goes from "cleared" to "invested." The first disbursement will likely occur by the end of this week, and then every two weeks thereafter.

If you invested $1500, you will soon receive an email from Fisher Wallace requesting a shipping address.

Thanks and be well!

Kelly Roman

CEO, Fisher Wallace

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.